



## News Release

---

Alliance to develop products for a wide range of animal species:

### **Bayer HealthCare and Juvaris BioTherapeutics announce licensing agreement**

---

**Leverkusen, March 4, 2008** – The Animal Health Division of Bayer HealthCare AG and Juvaris BioTherapeutics, Inc. jointly announced today that the companies have executed a licensing agreement. Under the terms of the agreement, Bayer HealthCare will have complete access in the veterinary field to the Juvaris mono-immunotherapy and vaccine technology, which is being developed by Juvaris for human health care. The companies will evaluate and execute product development programs directed at immune stimulation and disease prevention in a variety of animal species.

In addition, the agreement anticipates that Bayer Animal Health will help financially support Juvaris' research, product formulation, development and GMP manufacturing activities to enable it to meet its alliance obligations. The license is worldwide in scope. The financial terms of the deal have not been disclosed.

In commenting on the transaction, Lykele van der Broek, President of Bayer's Animal Health Division and Member of the Executive Committee of Bayer HealthCare AG said, "We are excited about the opportunities the Juvaris technology offers us. The beauty about this cooperation is, that it is not just about one single product. It serves as a platform technology that helps us develop a wide range of applications in several species for numerous indications in preventing infectious diseases. This technology in combination with our in-house expertise dramatically expands our ability to develop new and innovative products that promote immune stimulation and disease prevention."

In commenting on behalf of Juvaris, Martin D. Cleary, Co-Founder and Chairman of the Board of Juvaris, said, "We are delighted to put this agreement in place with an established veterinary franchise such as Bayer Animal Health. The world's animal health marketplace is basically underserved and to have a company willing to develop products, for which there are currently no approved human counterparts, is truly unusual in this space. We look forward to a long and productive relationship with Bayer Animal Health."

The companies have created a joint steering committee made up of Bayer Animal Health and Juvaris BioTherapeutics executives to ensure the required tasks are properly understood and executed.

### **About Bayer HealthCare**

Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading innovative companies in the health care and medical products industry. The company combines the activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions. The company's pharmaceuticals business operates under the name Bayer Schering Pharma AG. Bayer HealthCare's aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide.

With sales of EUR 956 million (2007) the Animal Health Division is one of the world's leading manufacturers of veterinary drugs. The division manufactures and markets approximately 100 different veterinary drugs and care products for food-supplying animals and companion animals.

### **About Juvaris BioTherapeutics**

Juvaris BioTherapeutics was created in 2003 to develop an immunotherapeutic product platform for the treatment of infectious diseases and cancers using lipid-DNA complexes. Cationic lipids are formulated with non-coding DNA (plasmid) to create the JuvImmune (JVRS-100) Immunostimulant, a lipid-DNA complex, which as a single product will have utility in multiple infectious disease and cancer applications. The JuvImmune product has been shown to be at least 50-times more potent at triggering innate immune activation and interferon release than current immune stimulants.

When combined with disease-specific antigens, the technology creates JuvaVax vaccines capable of activating substantial antibody- and cell-mediated immune responses,

particularly induction of cytotoxic T lymphocytes (CTL). Immunological responses elicited by the lipid-DNA complexes have been successfully demonstrated in both prophylactic and therapeutic settings in a variety of mammals including rodents, rabbits, cats, dogs and non-human primates. This platform provides the opportunity to develop many disease-specific immunotherapy products, for which there are significant unmet medical needs.

The Company recently completed a Series A financing with Kleiner Perkins Caufield & Byers as the sole investor. It plans to start up to four clinical studies in 2008. The first will be a prophylactic vaccine for Influenza A, the second for chronic Hepatitis C, the third for Acute Myelogenous Leukemia (AML), and a fourth a therapy for chronic Hepatitis B. The Company encourages partnering inquiries and can be reached at its website @ [www.juvaris.com](http://www.juvaris.com).

Contact:

**Kerstin Nacken, phone: +49 2173-38 4019**

e-mail: [kerstin.nacken@bayerhealthcare.com](mailto:kerstin.nacken@bayerhealthcare.com)

**Just a click away – our press service with images and texts online:**

**[www.viva.vita.bayerhealthcare.com](http://www.viva.vita.bayerhealthcare.com)**

ken (2008-0099e)

**Forward-Looking Statements**

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at [www.bayer.com](http://www.bayer.com). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.